Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Glimepiride / pioglitazone price, strengths & recalls

Pharmacies pay $288.11 for 30 tablets of Glimepiride / pioglitazone 2 mg / 30 mg tablet this week, and from $288.11 to $309.63 across its 2 priced strengths and forms. Its official label last changed on December 15, 2025.

Generic
Pharmacies pay$288.11for 30 tablets of 2 mg / 30 mg tablet-10.8% in 4 weeks
Fair cash price
$341.83
Strengths
2
Makers
1
Updated
Nov 11

Glimepiride / pioglitazone price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
2 mg / 30 mg tablet$9.60$288.11 / 30 tablets-10.8%-8.7%
4 mg / 30 mg tablet$10.32$309.63 / 30 tablets-1.9%-9.5%

Supply status: shortages & recalls

No shortage reportedChecked Nov 17, 2026
No ongoing recallsNone on record

What did you pay for glimepiride / pioglitazone? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedDecember 15, 2025
Version9 of 7
EffectiveDec 12, 2025
Read the label

These highlights do not include all the information needed to use pioglitazone and glimepiride tablets safely and effectively. See full prescribing information for pioglitazone and glimepiride tablets. Pioglitazone and Glimepiride Tablets, for oral use Initial U.S. Approval: 2006

This drug has a boxed warning

WARNING: CONGESTIVE HEART FAILURE

Thiazolidinediones, including pioglitazone, which is a component of pioglitazone and glimepiride tablets, cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions (5.1)].

After initiation of pioglitazone and glimepiride tablets and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone and glimepiride tablets must be considered [see Warnings and Precautions (5.1)].

Pioglitazone and glimepiride tablets are not recommended in patients with symptomatic heart failure [see Warnings and Precautions (5.1)].

Initiation of pioglitazone and glimepiride tablets in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated [see Contraindications (4) and Warnings and Precautions (5.1)].

WARNING: CONGESTIVE HEART FAILURE

See full prescribing information for complete boxed warning.

Thiazolidinediones, including pioglitazone, which is a component of pioglitazone and glimepiride tablets, cause or exacerbate congestive heart failure in some patients. (5.1)

After initiation of pioglitazone and glimepiride tablets, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone and glimepiride tablets must be considered. (5.1)

Pioglitazone and glimepiride tablets are not recommended in patients with symptomatic heart failure. (5.1)

Initiation of pioglitazone and glimepiride tablets in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated. (4, 5.1)

Recent major changes (as listed on the label)

Warnings and Precautions | |

Urinary Bladder Tumors (5.6) | 12/2016 |

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA021925 · Takeda Pharms USA
First approved
July 28, 2006 (20 years ago)
Latest approved change
December 21, 2017
Approved label
PDF, Dec 26, 2017
Generic makers
None on the market
Last patent listed
June 8, 2028

Glimepiride / pioglitazone questions

How much does glimepiride / pioglitazone cost without insurance?

Pharmacies pay about $288.11 for 30 tablets of glimepiride / pioglitazone 2 mg / 30 mg tablet ($9.60 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $341.83. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is glimepiride / pioglitazone in shortage?

No shortage is reported for glimepiride / pioglitazone right now. We check the national shortage list every day.

Has glimepiride / pioglitazone been recalled?

No recalls are on record for glimepiride / pioglitazone.

When did the glimepiride / pioglitazone label last change?

The official label was last updated on December 15, 2025 (version 9). See what changed.

Talk about glimepiride / pioglitazone

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.